Key Takeaways
- Zealand Pharma experienced approximately 25% decline following Phase III survodutide trial results revealing substantial patient withdrawal rates
- Treatment discontinuation occurred in 23ā25% of survodutide participants due to gastrointestinal complications, compared to only 5.4% in the placebo group
- The drug demonstrated impressive weight reduction results reaching 16.6% versus placebo’s 3.2%
- Goldman Sachs highlighted that poor tolerability profile will probably restrict market penetration in the obesity treatment sector
- Wolfe Research maintained “outperform” stance with DKK750 target price, suggesting potential 129%+ gain from levels before the decline
Zealand Pharma (ZEAL) witnessed approximately 25% erosion in market capitalization Monday following the release of Phase III clinical trial results for survodutideāits obesity treatment developed with Boehringer Ingelheimāwhich demonstrated that approximately 25% of trial participants discontinued therapy due to adverse reactions.
Shares declined roughly 25% during Copenhagen trading sessions. Novo Nordisk, Zealand’s more prominent competitor in obesity therapeutics, experienced approximately 2% reduction the same day.
The SYNCHRONIZE-1 study enrolled 725 adults with obesity or overweight status without Type 2 diabetes over a 76-week period. Weight reduction achieved up to 16.6% using the efficacy estimand compared to 3.2% for placeboārepresenting robust headline efficacy.
However, the tolerability profile painted a concerning picture.
Treatment withdrawal rates reached 23.7% and 24.8% for the 3.6mg and 6mg dosing arms respectively, dramatically exceeding the placebo arm’s 5.4%. The primary driver: gastrointestinal adverse events, responsible for 17.8% and 20.2% of discontinuations across each active dose compared to merely 2.9% for placebo.
Goldman Sachs directly addressed these findings, indicating that poor tolerability will probably constrain survodutide’s commercial adoption in the obesity treatment landscape.
Wolfe Research identified an additional confounding factor. Approximately 16.5% of placebo-arm participants utilized prohibited GLP-1 receptor agonist medications during the study period, artificially elevating placebo-arm weight loss and narrowing the observed treatment effect differential.
The research firm also highlighted how the trial’s inflexible protocol design contributed to elevated discontinuation figures, referencing investigator feedback regarding the challenges of conducting rigid versus adaptive studies.
Impressive Efficacy Results Provide Partial Offset
Notwithstanding the tolerability challenges, the efficacy data contained noteworthy positive elements.
A body composition substudy utilizing MRI scanning in 75 participants demonstrated survodutide 6mg achieved a 34% relative visceral fat reduction versus 11.8% for placebo. Hepatic fat decreased 63.1% compared to placebo’s 24.5%, and lean tissue constituted no more than 10.8% of total mass change at the maximum dose.
The companion SYNCHRONIZE-MASLD study, conducted over 48 weeks in 218 adults with obesity and metabolic-associated fatty liver disease, similarly succeeded. As many as 84.2% of survodutide-treated patients achieved at least 30% relative liver fat reduction, versus 24.3% receiving placebo. Body weight decreased 12.2% compared to 1% with placebo.
Zealand’s Remaining Commercial Opportunity
Zealand Pharma stands to receive high single- to low double-digit percentage royalties on worldwide survodutide revenues, plus ā¬315 million in remaining milestone payments. Boehringer Ingelheim maintains complete accountability for clinical development and market commercialization.
Wolfe Research preserved its “outperform” recommendation with a DKK750 valuation targetārepresenting approximately 130% appreciation potential from pre-decline closing prices.
Separately, Novo Nordisk announced that prescription volume for its Wegovy oral weight-loss medication has surpassed three million since the tablet’s market introduction in early January.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
